Abstract
The detoxification mechanisms occurring in the cells and tissues of the body are necessary to maintain homeostasis. The CYP enzymes family support these mechanisms, take a part in the pharmacokinetics of drugs and neutralizing xenobiotics. The predominant sub-family of CYP enzymes are CYP3A5 coded by gene CYP3A5. The distribution of CYP3A5 variants varies in different ethnic groups, while the absence of functional CYP3A5, linked to diminished enzymatic function, is most frequent. Knowledge about distribution of CYP3A5 variants in different ethnic groups is important to establish the clinical relevance of screening for these variants and to optimize and individualize pharmacotherapy. The aim of the study was to establish the distribution of variants *1 and *3 of CYP3A5 gene and compare our results with those from other Central-Eastern and South European populations. The studied population consisted of 469 healthy adults: Belarusians, Bosnians and Poles (241 female and 228 male) mean age 50.68 (±16.09) y. DNA was extracted from buccal swabs, and for the *1 and*3 variants of CYP3A5 gene, the PCR-RFLP was performed. The frequency of the CYP3A5*3 variant in Belarussians, Bosnians and Poles was 98.44, 97.89 and 94.56%, followed by the *1 variant: 1.56, 2.11 and 5.44%, respectively. We showed that Central-Eastern and South European populations are characterized by high variability of CYP3A5 variants. This may be taken into consideration in the prognosis of pharmacotherapy efficacy in the studied populations.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Zhou, S.F.: Polymorphism of human cytochrome P450 2D6 and its clinical significance. Clin. Pharmacokinet. 48(11), 689–723 (2009)
Zhang, Y.P., Zuo, X.C., Huang, Z.J., Cai, J.J., Wen, J., Duan, D.D., et al.: CYP3A5 polymorphism, amlodipine and hypertension. J. Hum. Hypertens. 28(3), 145–149 (2014)
Wang, B.S., Liu, Z., Xu, W.X., Sun, S.L.: CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression. Tumour Biol. 34(4), 2357–2366 (2013)
Du, J., Zhang, A., Wang, L., Xuan, J., Yu, L., Che, R., et al.: Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients. J. Psychopharmacol. 4(7), 1115–1120 (2010)
Lee, S.J., van der Heiden, I.P., Goldstein, J.A., van Schaik, R.H.N.: A new CYP3A5 variant, CYP3A5*11, is shown to be defective in nifedipine metabolism in a recombinant cDNA expression system. Drug Metab. Dispos. 35(1), 67–71 (2007)
Shuichi, Fukuen, Tsuyosh, Fukuda, Hiromi, Maune, Ikenaga, Yuka, Isamu, Yamamoto, Tadanobu, Inaba, et al.: Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5 *3 and *6, in a Japanese population. Pharmacogenetics 12(4), 331–334 (2002)
Roy, J.N., Lajoie, J., Zijenah, L.S., Barama, A., Poirier, C., Ward, B.J., et al.: CYP3A5 genetic polymorphisms in different ethnic populations. Drug Metab. Dispos. 33(7), 884–887 (2005)
Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J., et al.: Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383–391 (2001)
Kronbach, T., Fischer, V., Meyer, U.A.: Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporinemetabolizing enzyme explains interactions of cyclosporine with other drugs. Clin. Pharmacol. Ther. 43(6), 630–635 (1988)
Aoyama, T., Yamano, S., Waxman, D.J., Lapenson, D.P., Meyer, U.A., Fischer, V., et al.: Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J. Biol. Chem. 264(18), 10388–10395 (1989)
Chou, F.C., Tzeng, S.J., Huang, J.D.: Genetic polymorphism of cytochrome P450 3A5 in Chinese. Drug Metab. Dispos. 29(9), 1205–1209 (2001)
Shih, P.S., Huang, J.D.: Pharmacokinetics of midazolam and 1′-hydroxymidazolam in Chinese with different CYP3A5 genotypes. Drug Metab. Dispos. 30(12), 1491–1496 (2002)
van Schaik, R.H., van der Heiden, I.P., van den Anker, J.N., Lindemans, J.: CYP3A5 variant allele frequencies in Dutch Caucasians. Clin. Chem. 48(10), 1668–1671 (2002)
Semiz, S., Dujić, T., Ostanek, B., Prnjavorac, B., Bego, T., Malenica, M., et al.: Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina. Med. Glas. (Zenica) 8(1), 84–89 (2011)
Adler, G., Łoniewska, B., Parczewski, M., Kordek, A., Ciechanowicz, A.: Frequency of common CYP3A5 gene variants in healthy Polish newborn infants. Pharmacol Rep. 61(5), 947–951 (2009)
Atanasova, S.Y., von Ahsen, N., Toncheva, D.I., Dimitrov, T.G., Oellerich, M., Armstrong, V.W.: Genetic polymorphisms of cytochrome P450 among patients with Balkan endemic nephropathy (BEN). Clin. Biochem. 38(3), 223–228 (2005)
Ganoci, L., Božina, T., Mirošević Skvrce, N., Lovrić, M., Mas, P., et al.: Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population. Drug Metab. personalized Ther. 32(1), 11–21 (2017)
Arvanitidis, K., Ragia, G., Iordanidou, M., Kyriaki, S., Xanthi, A., Tavridou, A., et al.: Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam. Clin. Pharmacol. 21(4), 419–426 (2007)
Turolo, S., Tirelli, A.S., Ferraresso, M., Ghio, L., Belingheri, M., Groppali, E., et al.: Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep. 62(6), 1159–1169 (2010)
Krasniqi, V., Dimovski, A., Bytyqi, H.Q., Eftimov, A., Šimičević, L., Božina, N.: Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population. Arh. Hig. Rada. Toksikol. 68(3), 180–184 (2017)
Kapedanovska Nestorovska, A., Jakovski, K., Naumovska, Z., Hiljadnikova Bajro, M., Sterjev, Z., Eftimov, A., et al.: Distribution of the most common genetic variants associated with a variable drug response in the population of the Republic of Macedonia. Balkan J. Med. Genet. 17(2), 5–14 (2014)
Oliveira, E., Marsh, S., van Booven, D.J., Amorim, A., Prata, M.J., McLeod, H.L.: Pharmacogenetically relevant polymorphisms in Portugal. Pharmacogenomics 8(7), 703–712 (2007)
Mustafina, O.E., Tuktarova, I.A., Karimov, D.D., Somova, R.S., Nasibullin, T.R.: CYP2D6, CYP3A5, and CYP3A4 gene polymorphism in Russian, Tatar, and Bashkir populations [Article in Russian]. Genetika 51(1), 109–119 (2015)
Gervasini, G., Vizcanio, S., Gaisba, C., Carrillo, J.A., Benitez, J.: Differences in CYP3A5 genotype distribution and combination with other polymorphisms between Spaniards and other Caucasian populations. Ther. Drug Monit. 27(6), 819–821 (2005)
http://www.ema.europa.eu. Access Aug 2018
http://www.fda.gov. Access Aug 2018
Zanger, U.M., Schwab, M.: Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138(1), 103–141 (2013)
Acknowledgements
This work was funded in part by the Pomeranian Medical University, Szczecin, Poland (decision reference number WNoZ-307-02/S/18).
Declaration of Interest
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this paper
Cite this paper
Adler, G. et al. (2020). Landscape of CYP3A5 Variants in Central-Eastern and South European Populations. In: Badnjevic, A., Škrbić, R., Gurbeta Pokvić, L. (eds) CMBEBIH 2019. CMBEBIH 2019. IFMBE Proceedings, vol 73. Springer, Cham. https://doi.org/10.1007/978-3-030-17971-7_78
Download citation
DOI: https://doi.org/10.1007/978-3-030-17971-7_78
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-17970-0
Online ISBN: 978-3-030-17971-7
eBook Packages: EngineeringEngineering (R0)